Results 151 to 160 of about 1,034,896 (346)

U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.

open access: yesThe Oncologist, 2002
M. Cohen   +8 more
semanticscholar   +1 more source

SKOOTS: Skeleton‐Oriented Object Segmentation for Mitochondria in High‐Resolution Cochlear EM Datasets

open access: yesAdvanced Science, EarlyView.
Skeleton‐oriented object segmentation (SKOOTS) introduces a new strategy for 3D mitochondrial instance segmentation by predicting explicit skeletons rather than relying on boundary cues. This approach enables robust analysis of densely packed organelles in large FIB‐SEM datasets.
Christopher J. Buswinka   +3 more
wiley   +1 more source

Synergistic Mn‐MOF Activation of Pistol Ribozymes for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A Mn2+‐based metal–organic framework delivers a catalytic Pistol ribozyme for targeted PD‐L1 mRNA cleavage in tumor cells, with the released Mn2+ not only inducing immune activation in immune cells but also increasing the Pistol ribozyme catalytic activity.
Ming Zhao   +10 more
wiley   +1 more source

Investigation on Administration Schedule Practice of Hypnotic Drugs of Outpatients.

open access: yesJapanese Journal of Hospital Pharmacy, 1992
KENZO YONEZAWA   +6 more
openaire   +2 more sources

Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration

open access: yesAdvanced Science, EarlyView.
Bone regeneration by mesenchymal stem cells is strongly influenced by immune signals. This study shows that priming stem cells with regulatory immune cells or an inflammation‐resolving lipid molecule enhances bone formation through distinct immune pathways.
Salwa Suliman   +5 more
wiley   +1 more source

Engineered Bacteria Factory Integrating Drug Delivery and Antibody Manufacture for Activating the STING Signal Pathway Mediated Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong   +9 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy